[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100083677":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":52,"collaborators":7,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":7,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":7,"targetDuration":7,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Asociación para Evitar la Ceguera en México","OTHER",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","intravitreal injection",[13],{"name":14,"affiliation":5,"role":15},"Maria Martínez-Castellanos, MD","PRINCIPAL_INVESTIGATOR",[17,23],{"name":18,"role":19,"phone":20,"phoneExt":21,"email":22},"Hugo Quiroz-Mercado, MD","CONTACT","525510841400","1171","retinamex@yahoo.com",{"name":24,"role":19,"phone":20,"phoneExt":21,"email":22},"Maria A Martínez-Castellanos, MD",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Asociación para Evitar la Ceguera en México Hospital \"Luis Sanchez Bulnes\"","RECRUITING","Mexico City","Mexico DF","04030","Mexico","MX",{"type":35,"coordinates":36},"Point",[37,38],-99.12766,19.42847,{"lat":38,"lon":37},[41,43,45,48,50],{"name":42,"role":19,"phone":20,"phoneExt":21,"email":22},"Maria A Martinez-Castellanos, MD",{"name":44,"role":15,"phone":7,"phoneExt":7,"email":7},"Maria Martinez-Castellanos, MD",{"name":46,"role":47,"phone":7,"phoneExt":7,"email":7},"Hugo A Quiroz-Mercado, MD","SUB_INVESTIGATOR",{"name":49,"role":47,"phone":7,"phoneExt":7,"email":7},"Myriam L Hernandez-Rojas, MD",{"name":51,"role":47,"phone":7,"phoneExt":7,"email":7},"Jans Fromow-Guerra, MD",{"type":53,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100083677","phase-2-antiangiogenic-therapy-with-bevacizumab-in-retinopathy-of-prematurity-structural-outcome-100083677",false,"NCT00346814","Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome","Inclusion Criteria:\n\n* Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY\n\nExclusion Criteria:\n\n* PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER","ALL","1 Month","12 Months","INTERVENTIONAL",[65,66],"PHASE2","PHASE3","Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity",[69],"Retinopathy of Prematurity",[71,72],"Retinopathy of prematurity","antiangiogenic therapy","2024-07-30",{"date":75,"type":76},"2024-07-31","ACTUAL",{"date":78,"type":76},"2007-07",{"date":80,"type":81},"2024-11","ESTIMATED",{"name":5,"class":6},1]